Dabigatran and myocardial infarction: Meta-illusion?

Archives of Internal Medicine

Volumn 172, Issue 10, 2012, Pages 823-

  Correia, Luis C L ^a   Lopes, Antonio A ^b  

^a School of Medicine and Public Health of the State of Bahia   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL; STROKE;

ACUTE CORONARY SYNDROME; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; THROMBOEMBOLISM;

EID: 84861659315     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.836     Document Type: Note

References (2)

1. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397-402.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.